Nascimento FC, Leitão AMN, Saldarriaga RLM, Mendonça CLM, Ríos GBBE

Language: Portugués
References: 14
Page: 193-199
PDF size: 144.77 Kb.

ABSTRACT

Introduction: rheumatoid arthritis depends on inflammatory factors such as receptor activator of nuclear factor κB Ligand /Osteoprotegerin, essential for bone metabolism and thus, has a great propensity for developing low bone mass.
Objectives: to evaluate the influence of renal function and inflammation in bone mass of rheumatoid arthritis patients positive before menopause.
Methods: 50 women, 26 with rheumatoid arthritis and 24 healthy control group completed the study.
Results: we investigated patients 24 to 49 years. The results demonstrate significant increases in leukocytes, rheumatoid factor, erythrocyte sedimentation, the pyruvic transaminase, and a tendency to increased gamma glutamyl transpeptidase in the rheumatoid arthritis group. Also differences were found with increased levels of sodium and chlorine in these groups compared to controls. A significant change from the urinary pH, more acid in patients with rheumatoid arthritis. There was found no difference with regard to abnormal elements, including for the presence of proteinuria between groups. Patients with rheumatoid arthritis has decreased clearance, but without significant difference compared to the control group.
Conclusion: the presence of inflammation is the main reason for developing low bone mass in patients with rheumatoid arthritis.

REFERENCES

1. Haugeberg G, Orstavik RE, KveinTK. Effects of rheumatoid arthritis on bone. Current Opun Rheumatol. 2003;15:469-2003.

2. Bolon B, Shalboub V, KostenuikPJ et al. Osteoprotegerinna endogenous antoosteoclast factor for proteting bone in rheumatoid arthritis. Arthritis. 2002;46:3121-35.

3. Nevitt MC. Epidemiology of osteoporosis. Rheum Dis Clin North Am. 1994;20:535-59.

4. Motta LCM, Cruz BA, Brenol CV, Pereira IA, Rezende – FronzaLS, Bertolo MA et al. Consenso 2012 de Sociedade Brasileira de Reumatologia para o tratamento da Artrite Reumatoide. Rev Bras Reumatol. 2012;52:135-74.

5. Dolan AL, Moniz C, Abraha H, Pitt P. Does active treatment of rheumatoid arthritis limit disea SE – associated bone loss? J Rheumatol. 2002;41:1047-51.

6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.

7. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson, DT, Bingham CO, & Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & Rheumatism, 2010;62(9):2569-81.

8. Steinbrocker O, Trarger CH, Batterman RC. Therapeutic critera in rheumatoid arthritis. JAMA. 1949;140:659-62.

9. Kiebzak GM, Leamy L J, Pierson L M, Nord RH, Zhang, ZY. Measurement precision of body composition variables using the lunar DPX-L densitometer. Journal of Clinical Densitometry. 2000; 3(1):35-41.

10. Grahnemo L, Jochems C, Andreson A, Engdahl C, Ohlsson C, Islandr U, Carlsten H. Possible role of lymphocytes in glucocorticoid-induced increase in trabecular bone mineral density. J Endrocrinol. 2015;224:97-108.

11. LiS Miller CH, Giannopoulou E, Xu X, IvaskkivLB, Zhao B. RBP-J imposes a requirement for ITAM-meddiate costimulation of osteoclasto genesis. J Clin Invest. 2014;124:5057-73.

12. Effects of specific inhibition of cyclooxigenase - 2 on sodium balance, hemodynamics, and vasoactive ecosanoids. J Pharmacol Exp Therap. 1999;289;735-41.

13. Singh G. Fries JF, Williams CA et al. Toxicity profiles of disease modifying antirheumatic drugsin rheumatoid arthritis. J Rheumatol. 1991;18:188-96.

14. Azevedo MNL, Nunes JF, Tuma MFF. Bone mineral density at 45 years old age before menopause. Journal of National Medical Association. 2009;101:788-92.